Cancer drug developers up on presenting promising data from studies

ImmunoGen

05/06/2023 12:49

** Shares of cancer drug developers rise premarket after the
companies over the weekend presented positive data from clinical
studies at the 2023 American Society of Clinical Oncology (ASCO)
annual meeting
    ** Shares of ImmunoGen Inc  IMGN.O  up 6.7% at $15.3,
Evaxion Biotech  EVAX.O  up 42.5% at $2.11, Day One
Biopharmaceuticals Inc  DAWN.O  rises 26.8% to $17.25
    ** DAWN's data from mid-stage study for its investigational
monotherapy in a type of brain tumor shows overall response rate
of 67% and clinical benefit rate of 93% 
    ** IMGN's experimental ovarian cancer therapy when compared
to chemotherapy showed 35% reduction in the risk of death or
length of time the disease does not get worse during and after
the treatment in a late-stage study
    ** Brokerage William Blair says IMGN's therapy is first to
demonstrate an overall survival benefit in ovarian cancer
patients, which will significantly reduce regulatory risk and
likely bolster further adoption
    ** EVAX's experimental drug to treat patients with skin
cancer showed positive clinical response in 8 out of 12 patients
in an early-stage study, and was safe to use 

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))